Provided by Tiger Trade Technology Pte. Ltd.

Gilead Sciences

149.07
-1.3600-0.90%
Volume:599.18K
Turnover:89.53M
Market Cap:184.95B
PE:-57.01
High:151.16
Open:151.16
Low:148.30
Close:150.43
52wk High:157.29
52wk Low:114.02
Shares:1.24B
Float Shares:1.24B
Volume Ratio:0.60
T/O Rate:0.05%
Dividend:3.22
Dividend Rate:2.16%
EPS(TTM):-2.6150
EPS(LYR):6.78
ROE:-20.68%
ROA:14.09%
PB:15.64
PE(LYR):21.99

Loading ...

Moderna Inc. Stock Slips 7.8%, Underperforms Peers

Dow Jones
·
Oct 07

Cognizant, Gilead Sign 5-Year Tech Extension Covering DevOps, AI Tools

MT Newswires Live
·
Oct 06

Cognizant announces five-year extension of its work with Gilead Sciences

TIPRANKS
·
Oct 06

Cognizant - to Support Gilead's Devops and AI Tools Across Selected Technology Programs

THOMSON REUTERS
·
Oct 06

Cognizant Expands AI-Enabled Devops Capabilities for Gilead Sciences

THOMSON REUTERS
·
Oct 06

Entera Bio Appoints Ex-Gilead Executive Laura Hamill to Board of Directors

Reuters
·
Oct 06

From Lilly Deal to Market Darling: Inside Ginkgo's 120% Monthly Run

Bellwether Stocks Movement
·
Oct 06

Moderna Inc. Stock Rises 6.9%, Outperforms Peers

Dow Jones
·
Oct 06

Nurix, Gilead Extend Research Term for Oncology Program by Two Years for $10 Million Fee

Reuters
·
Oct 05

Nurix Extends Gilead Collaboration for Oncology Program

Reuters
·
Oct 05

Nurix - Eligible for up to $1.30 Bln in Total Payments as of May 31, 2026

THOMSON REUTERS
·
Oct 05

Nurix - Eligible for Mid-Single-Digit to Low-Teens Percentage Tiered Royalties

THOMSON REUTERS
·
Oct 05

Nurix - to Receive $10 Mln Research Term Extension Fee

THOMSON REUTERS
·
Oct 05

Nurix - Retains Co-Development and 50/50 Profit Sharing Options on Two U.S. Programs

THOMSON REUTERS
·
Oct 05

One Molecule, Three Diseases, $1.55 Billion — Inside CSL's Bet

Bellwether Stocks Movement
·
Oct 05

Merck Doubled Off Its Lows — And Analysts Still See More Room

Bellwether Stocks Movement
·
Oct 05

CSL Bets $1.6 Billion on a Drug That Hasn't Finished Phase 2

Bellwether Stocks Movement
·
Oct 05

Bayer Bets $2.2 Billion That America Is Still The Best Place To Make Drugs

Macro World​
·
Oct 03

23.3% Vs 14.8%: Lilly's New Data Just Changed The Obesity Drug Playbook

Bellwether Stocks Movement
·
Oct 03

Gilead CEO Daniel O’Day Disposes of USD 2,216,507.50 in Common Shares

Reuters
·
Oct 03